Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.
Inhibition of dsRNA-activated protein kinase (PKR), not only attenuates muscle atrophy in a murine model of cancer cachexia (MAC16), but it also inhibits tumour growth. In vitro the PKR inhibitor maximally inhibited growth of MAC16 tumour cells at a concentration of 200 nM, which was also maximally effective in attenuating phosphorylation of PKR and of eukaryotic initiation factor (eIF)2 on the alpha-subunit. There was no effect on the growth of the MAC13 tumour, which does not induce cachexia, even at concentrations up to 1,000 nM. There was constitutive phosphorylation of PKR and eIF2alpha in the MAC16, but not in the MAC13 tumour, while levels of total PKR and eIF2alpha were similar. There was constitutive upregulation of nuclear factor-kappaB (NF-kappaB) in the MAC16 tumour only, and this was attenuated by the PKR inhibitor, suggesting that it arose from activation of PKR. In MAC16 alone the PKR inhibitor also attenuated expression of the 20S proteasome. The PKR inhibitor potentiated the cytotoxicity of both 5-fluorouracil and gemcitabine to MAC16 cells in vitro. These results suggest that inhibitors of PKR may be useful therapeutic agents against tumours showing increased expression of PKR and constitutive activation of NF-kappaB, and may also prove useful in sensitising tumours to standard chemotherapeutic agents.
Nutritional Biomedicine, School of Life and Health Sciences, Aston University, Birmingham, UK.
Helen L
HL
Eley
Pria S
PS
McDonald
Steven T
ST
Russell
Michael J
MJ
Tisdale
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D015153:Blotting, Western; D049109:Cell Proliferation; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D004789:Enzyme Activation / Q000187:drug effects; D005472:Fluorouracil / Q000494:pharmacology; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D010766:Phosphorylation / Q000187:drug effects; D046988:Proteasome Endopeptidase Complex / Q000235:genetics / Q000378:metabolism; D014176:Protein Biosynthesis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D012330:RNA, Double-Stranded / Q000187:drug effects*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D019892:eIF-2 Kinase / Q000037:antagonists & inhibitors*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D012330:RNA, Double-Stranded; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D019892:eIF-2 Kinase; D046988:Proteasome Endopeptidase Complex; D005472:Fluorouracil; D000093542:Gemcitabine